A clinical research study to evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by vancomycin-resistant Enterococcus (VRE) or methicillin-resistant Staphylococcus aureus [MRSA]

Trial Profile

A clinical research study to evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by vancomycin-resistant Enterococcus (VRE) or methicillin-resistant Staphylococcus aureus [MRSA]

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2013

At a glance

  • Drugs Tigecycline (Primary)
  • Indications Bacteraemia; Enterococcal infections; Gram-positive infections; Intra-abdominal infections; Methicillin-resistant Staphylococcus aureus infections; Pneumonia; Skin infections; Staphylococcal infections; Vancomycin-resistant enterococcal infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Feb 2013 Actual initiation date (Oct 2003) added as reported by ClinicalTrials.gov.
    • 07 Feb 2013 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
    • 27 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top